A Relapse Prevention Study Evaluating the Efficacy of Vortioxetine in Adults with Major Depressive Disorder

Brief Description Of Study

This study will evaluate the effectiveness of Vortioxetine (aka Brintellix) in the prevention of depression relapse.

Clinical Study Identifier: TX1052

Detailed Study Description

This study is being conducted to evaluate the long-term maintenance effects of individuals treated with vortioxetine (aka, Brintellix) in the prevention of depression relapse. Participants will be enrolled into a 8-16 weeks open-label treatment period. During the open-label period, all subjects will receive 10 mg Vortioxetine. At the end of the open label patients have option to go into 16 -52 week, double blind study to assess the Efficacy and Safety of Vortioxetine (5, 10 and 20 mg) in Adults with MDD.

Contact research investigator to learn more about this study by filling out the form below.


To: Research Study Investigator
Subject: I am interested in participating in your Research Study
Dear Investigator,
I'm interested in learning more about and participating in your research study named: A Relapse Prevention Study Evaluating the Efficacy of Vortioxetine in Adults with Major Depressive Disorder
I am hoping to hear back from you and discuss details of the study

By clicking "Contact Research Team", your contact information will be sent directly to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.